301 related articles for article (PubMed ID: 24924415)
1. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Katz TA; Vasilatos SN; Harrington E; Oesterreich S; Davidson NE; Huang Y
Breast Cancer Res Treat; 2014 Jul; 146(1):99-108. PubMed ID: 24924415
[TBL] [Abstract][Full Text] [Related]
2. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
3. Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2).
Mino K; Nishimura S; Ninomiya S; Tujii H; Matsumori Y; Tsuchida M; Hosoi M; Koseki K; Wada S; Hasegawa M; Sasaki R; Murakami-Yamaguchi Y; Narita H; Suzuki T; Miyata N; Mizukami T
Biosci Biotechnol Biochem; 2014; 78(6):1010-7. PubMed ID: 25036127
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.
Chen L; Vasilatos SN; Qin Y; Katz TA; Cao C; Wu H; Tasdemir N; Levine KM; Oesterreich S; Davidson NE; Huang Y
Oncotarget; 2017 Oct; 8(47):81737-81753. PubMed ID: 29137219
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
7. Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation.
Fang R; Barbera AJ; Xu Y; Rutenberg M; Leonor T; Bi Q; Lan F; Mei P; Yuan GC; Lian C; Peng J; Cheng D; Sui G; Kaiser UB; Shi Y; Shi YG
Mol Cell; 2010 Jul; 39(2):222-33. PubMed ID: 20670891
[TBL] [Abstract][Full Text] [Related]
8. Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Yang Y; Yin X; Yang H; Xu Y
Mol Cell; 2015 Apr; 58(1):47-59. PubMed ID: 25773598
[TBL] [Abstract][Full Text] [Related]
9. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
Lim S; Janzer A; Becker A; Zimmer A; Schüle R; Buettner R; Kirfel J
Carcinogenesis; 2010 Mar; 31(3):512-20. PubMed ID: 20042638
[TBL] [Abstract][Full Text] [Related]
10. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeKo-1 and MOLT-4 cells.
Zou ZK; Huang YQ; Zou Y; Zheng XK; Ma XD
Int J Mol Med; 2017 Aug; 40(2):319-328. PubMed ID: 28627608
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.
Huang Y; Vasilatos SN; Boric L; Shaw PG; Davidson NE
Breast Cancer Res Treat; 2012 Feb; 131(3):777-89. PubMed ID: 21452019
[TBL] [Abstract][Full Text] [Related]
12. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Ramadoss S; Guo G; Wang CY
Oncogene; 2017 Jan; 36(1):47-59. PubMed ID: 27270439
[TBL] [Abstract][Full Text] [Related]
13. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
14. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
[TBL] [Abstract][Full Text] [Related]
15. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors.
Chik F; Szyf M
Carcinogenesis; 2011 Feb; 32(2):224-32. PubMed ID: 20980350
[TBL] [Abstract][Full Text] [Related]
16. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
17. Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells.
Han H; Yang X; Pandiyan K; Liang G
PLoS One; 2013; 8(9):e75136. PubMed ID: 24040395
[TBL] [Abstract][Full Text] [Related]
18. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.
Nguyen CT; Weisenberger DJ; Velicescu M; Gonzales FA; Lin JC; Liang G; Jones PA
Cancer Res; 2002 Nov; 62(22):6456-61. PubMed ID: 12438235
[TBL] [Abstract][Full Text] [Related]
19. LSD2 Is an Epigenetic Player in Multiple Types of Cancer and Beyond.
Kim HM; Liu Z
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785960
[TBL] [Abstract][Full Text] [Related]
20. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
